Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVD-Dara in Relapsed or Refractory Multiple Myeloma
NCT05408026Phase 2Withdrawn
- Sponsor
- Alliance Foundation Trials
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Alliance Foundation Trials. Planned start Oct 2022; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05408026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408026.